Duality Biologics and BioNTech Share Promising Results from BNT324/DB-1311 Clinical Trials at ESMO Asia 2024 Recent findings from Duality Biologics and BioNTech reveal BNT324/DB-1311's efficacy in treating advanced solid tumors, showcasing a favorable safety profile.

Duality Biologics and BioNTech Share Promising Results from BNT324/DB-1311 Clinical Trials at ESMO Asia 2024 #China #Suzhou #Duality_Biologics #BioNTech #BNT324